참고문헌
- Cappuzzo F, Ciuleanu T, Stelmakh L, et al (2010). Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 11, 521-9. https://doi.org/10.1016/S1470-2045(10)70112-1
- Chen X, Zhu Q, Liu Y, et al (2014). Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study. PLoS One, 9, 95897. https://doi.org/10.1371/journal.pone.0095897
- Ellis PM, Blais N, Soulieres D, et al (2011). A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol, 6, 1379-91. https://doi.org/10.1097/JTO.0b013e318220cb8e
- Feld R, Sridhar SS, Shepherd FA, et al (2006). Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol, 1, 367-76. https://doi.org/10.1097/01243894-200605000-00018
- Fossella FV, DeVore R, Kerr RN, et al (2000). Randomized phase iii trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The tax 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol, 18, 2354-62.
- Fukuoka M, Yano S, Giaccone G, et al (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol, 21, 2237-46. https://doi.org/10.1200/JCO.2003.10.038
- Govindan R, Page N, Morgensztern D, et al. (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44 https://doi.org/10.1200/JCO.2005.04.4859
- Gridelli C, Ciardiello F, Gallo C, et al (2012). First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol, 30, 3002-11. https://doi.org/10.1200/JCO.2011.41.2056
- Hanna N, Shepherd FA, Fossella FV, et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97. https://doi.org/10.1200/JCO.2004.08.163
- Hotta K, Fujiwara Y, Kiura K, et al (2007) Relationship between response and survival in more than 50, 000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol, 2, 402-7. https://doi.org/10.1097/01.JTO.0000268673.95119.c7
- Hu X, Han B, Gu A, et al (2014). A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). Lung Cancer, 86, 207-12. https://doi.org/10.1016/j.lungcan.2014.08.014
- Jemal A, Bray F, Center MM, et al (2011) Global cancer statistics. CA Cancer J Clin, 61, 69-90 https://doi.org/10.3322/caac.20107
- Leighl NB (2012). Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol, 19, 52-8.
- Liu D, Jiang J, Hu P, et al (2009). Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 877, 3781-6. https://doi.org/10.1016/j.jchromb.2009.08.055
- Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39. https://doi.org/10.1056/NEJMoa040938
- National Comprehensive Cancer Network. Non Small Cell Lung Cancer. 2013, cited 2013-10-30. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
- Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500. https://doi.org/10.1126/science.1099314
- Pan H, Liu R, Li S, et al (2014). Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes. Cell Biochem Biophys, 70, 553-8. https://doi.org/10.1007/s12013-014-9955-y
- Ramalingam SS, Dahlberg SE, Langer CJ, et al. (2008) Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol, 26, 60-5. https://doi.org/10.1200/JCO.2007.13.1144
- Scagliotti GV, Parikh P, von Pawel J, et al (2008). Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51. https://doi.org/10.1200/JCO.2007.15.0375
- Schiller JH, Harrington D, Belani CP, et al (2002). On behalf of the eastern cooperative oncology group comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
- Shao L, Zhang B, He C, et al (2014). Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancerafter failure of chemotherapy. Chin Med J (Engl), 127, 266-71.
- Shepherd FA, Dancey J, Ramlau R, et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103.
- Shepherd FA, Rodrigues PJ, Ciuleanu T, et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32. https://doi.org/10.1056/NEJMoa050753
- Soda M, Choi YL, Enomoto M, et al (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-6. https://doi.org/10.1038/nature05945
- Tan F, Shen X, Wang D, et al (2012). Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer, 76, 177-182. https://doi.org/10.1016/j.lungcan.2011.10.023
- Kris MG, Natale RB, Herbst RS, et al (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 290, 2149-2158. https://doi.org/10.1001/jama.290.16.2149
- Yang X, Zhang H, Qin N, et al (2013). Clinical observation of icotinib hydrochloride in first-line therapy for pulmonary adenocarcinoma. Zhongguo Fei Ai Za Zhi, 16, 364-8.
- Zhao Q, Shentu J, Xu N, et al (2011). Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer, 73, 195-202. https://doi.org/10.1016/j.lungcan.2010.11.007
- Zheng X, Liu G, Wang S, et al (2014). A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinomacancer without indication for chemotherapy. Oncol Lett, 8, 1563-6.
- Zheng Y, Fang W, Deng J, et al (2014). Sequential treatment of icotinib after first-line pemetrexed in advanced lungadenocarcinoma with unknown EGFR gene status. J Thorac Dis, 6, 958-64.
피인용 문헌
- Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
- A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485